Clinical Trial Detail

NCT ID NCT02057133
Title A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib + Loperamide + Pertuzumab + Trastuzumab

Abemaciclib + Fulvestrant + LY3023414

Abemaciclib + Letrozole

Abemaciclib + Exemestane

Abemaciclib

Abemaciclib + Everolimus + Exemestane

Abemaciclib + Anastrozole

Abemaciclib + Tamoxifen

Abemaciclib + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST